WHAT IS CLAIMED IS:

1. Use of an agent that inhibits binding of PSD-95 to an NMDAR2B subunit in the manufacture of a medicament to treat a subarachnoid hemorrhage,

wherein the agent is a peptide having an amino acid sequence consisting or comprising of X_1tSX_2V (SEQ ID NO:7), wherein t and S are alternative amino acids, X_1 is selected from among E, Q, and A, X_2 is selected from among A, Q, D, N, (N-Methyl)-A, (N-methyl)-Q, (N-methyl)-D, and (N-methyl)-N and the peptide is linked to an internalization peptide or is lipidated thereby facilitating passage of the peptide across a cell membrane or the blood brain barrier.

2. The use of claim 1, wherein the subarachnoid hemorrhage is the result of physical trauma.

3. The use of any preceding claim, wherein the subarachnoid hemorrhage occurs spontaneously.

4. The use of claim 3, wherein the subarachnoid hemorrhage is due to a ruptured aneurysm.

5. The use of claim 3, wherein the subarachnoid hemorrhage is due to arteriovenous malformation.

6. The use of any preceding claim, wherein the agent inhibits development of neurocognitive deficits in the subject.

7. The use of any preceding claim, wherein the agent inhibits development of infarctions detectable by MRI.

8. The use of any preceding claim, wherein the subject receives endovascular surgery to repair a ruptured blood vessel causing the subarachnoid hemorrhage.

9. The use of claim 8, wherein the agent reduces pain resulting from endovascular surgery.

10. The use of claim 9, wherein the pain is along a path traversed by an endoscope used in performing the endoscopic surgery.

11. The use of any preceding claim, wherein the agent is a peptide having an amino acid sequence consisting or comprising of YGRKKRRQRRRKLSSIESDV (SEQ ID NO:6) or YGRKKRRQRRRKLSSIETDV (SEQ ID NO:37).

12. The use of any preceding claim wherein the agent is a myristoylated peptide.

13. The use of claim 12, wherein peptide has an amino acid sequence consisting or comprising of KLSSIESDV or KLSSIETDV.

14. The use of claim 12 or 13, wherein the myristoylation is at the N-terminus of the peptide.

15. The use of any preceding claim, wherein the agent is to be administered within a period starting 30 minutes before and ending 60 minutes after a surgery.